Results 1 to 10 of about 168,585 (146)

A comparison of paclitaxel and vinblastine induced giant cell formation in murine NK/Ly lymphoma

Біологічні студії, 2011
We compared giant cell formation in murine NK/Ly lymphoma under treatment with anticancer drugs – vinblastine or paclitaxel. It was found that vinblastine caused an appearance of bigger cells than paclitaxel did, whereas paclitaxel induced more rapid ...
R. O. Horbay, N. I. Kashchak, R. S. Stoika   +2 more
doaj   +1 more source

A new 2α,5α,10β,14β-tetraacetoxy-4(20),11-taxadiene (SIA) derivative overcomes paclitaxel resistance by inhibiting MAPK signaling and increasing paclitaxel accumulation in breast cancer cells. [PDF]

PLoS ONE, 2014
Tumor resistance due to multiple mechanisms seriously hinders the efficacy of chemotherapy drugs such as paclitaxel. The most widely studied P-glycoprotein inhibitors still have limited ability to reverse resistance in the clinic.
Mei Mei, Dan Xie, Yi Zhang, Jing Jin, Feng You, Yan Li, Jungui Dai, Xiaoguang Chen   +7 more
doaj   +1 more source

First line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel

International Journal of Nanomedicine, 2013
Neha Gupta, Hassan Hatoum, Grace K DyDepartment of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USAAbstract: Lung cancer is the leading cause of cancer mortality worldwide in both men and women.
Gupta N, Hatoum H, Dy GK
doaj  

FoxM1 Induced Paclitaxel Resistance via Activation of the FoxM1/PHB1/RAF-MEK-ERK Pathway and Enhancement of the ABCA2 Transporter

Molecular Therapy: Oncolytics, 2019
FoxM1 amplification in human pancreatic cancer predicts poor prognosis and resistance to paclitaxel. Here, a novel role between FoxM1 (FoxM1b and FoxM1c) and Prohibitin1 (PHB1) in paclitaxel resistance has been identified.
Chao Huang, Xin Zhang, Li Jiang, Limin Zhang, Ming Xiang, Hongyu Ren   +5 more
doaj   +1 more source

Proinflammatory Factors Mediate Paclitaxel-Induced Impairment of Learning and Memory

Mediators of Inflammation, 2018
The chemotherapeutic agent paclitaxel is widely used for cancer treatment. Paclitaxel treatment impairs learning and memory function, a side effect that reduces the quality of life of cancer survivors. However, the neural mechanisms underlying paclitaxel-
Zhao Li, Shuang Zhao, Hai-Lin Zhang, Peng Liu, Fei-Fei Liu, Yue-Xian Guo, Xiu-Li Wang   +6 more
doaj   +1 more source

Enhancement of paclitaxel transport and cytotoxicity by 7,3’,4’-trimethoxyflavone, a P-glycoprotein inhibitor

Journal of Pharmacy & Pharmaceutical Sciences, 2007
Purpose.: Paclitaxel has problems with respect to bioavailability and resistance. The aim of this study was to select a P-glycoprotein (Pgp)- inhibitory flavonoid to enhance paclitaxel bioavailability in the Caco-2 cell monolayer. Methods.
Ju-Mi Jeong, Cheol-Hee Choi
doaj   +1 more source

Rationalization of paclitaxel insensitivity of yeast β-tubulin and human βIII-tubulin isotype using principal component analysis

BMC Research Notes, 2012
Background The chemotherapeutic agent paclitaxel arrests cell division by binding to the hetero-dimeric protein tubulin. Subtle differences in tubulin sequences, across eukaryotes and among β-tubulin isotypes, can have profound impact on paclitaxel ...
Das Lalita, Bhattacharya Bhabatarak, Basu Gautam   +2 more
doaj   +1 more source

Paclitaxel-activated astrocytes produce mechanical allodynia in mice by releasing tumor necrosis factor-α and stromal-derived cell factor 1

Journal of Neuroinflammation, 2019
Background Paclitaxel is a widely used and potent chemotherapeutic agent for the treatment of cancer. However, patients receiving paclitaxel often develop an acute pain syndrome for which there are few treatment options. Astrocytes play an important role
Xiaojuan Liu, Raquel Tonello, Yuejuan Ling, Yong-Jing Gao, Temugin Berta   +4 more
doaj   +1 more source

Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer

International Journal of Nanomedicine, 2015
Liang Huang,1,2 Sheng Chen,1,2 Ling Yao,1,2 Guangyu Liu,1,2 Jiong Wu,1,2 Zhiming Shao1–3 1Department of Breast Surgery, Fudan University Shanghai Cancer Center/Cancer Institute, 2Department of Oncology, Shanghai Medical College, 3Institutes of ...
Huang L, Chen S, Yao L, Liu GY, Wu J, Shao ZM   +5 more
doaj  

Long Non-coding RNA CDKN2B Antisense RNA 1 Gene Contributes to Paclitaxel Resistance in Endometrial Carcinoma

Frontiers in Oncology, 2019
Endometrial cancer (EC) is the most common malignancy of the female reproductive tract. In this study, we clarified the clinical significance of CDKN2B antisense RNA 1 (CDKN2B-AS) gene, and its effects on paclitaxel sensitivity in EC.
Chao Shang, Cheng N. Ao, Chi C. Cheong, Lirong Meng   +3 more
doaj   +1 more source